Create a narrative

Eisai Community

TSE:4523 Community

1 Narratives written by author
0 Comments on narratives written by author
6 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 14 Analysts

LEQEMBI And LENVIMA Will Strengthen Market Position Despite Regulatory And Competitive Challenges

Key Takeaways LEQEMBI's expansion in the U.S., Japan, and China drives revenue growth, with innovations improving demand and margins through cost efficiencies. LENVIMA's revenue growth and new oncology combinations position Eisai for sustained earnings through diverse cancer treatment advancements.

JP¥5.00k

FV

17.1% undervalued

2.50%

Revenue growth p.a.

0

0

4

3 days ago